SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1878594902> ?p ?o ?g. }

Showing items 1 to 100 of ±128 with 100 items per page.

W1878594902 endingPage "83" @default.
W1878594902 startingPage "3479" @default.
W1878594902 abstract "Recent studies have underlined the role of nuclear receptors in the involvement of prostate cancer signalling pathways.A total of 84 benign prostate hyperplasia (BPH), 84 low risk prostate cancer (LPC) and 64 advanced disease (APC) cases were sampled on a tissue microarray (TMA) and stained for retinoic acid receptor (RAR)-α, retionoid X receptor (RXR)-α, liver X receptor (LXR)-α, farnesoid X receptor (FXR) and proliferate-activated receptor gamma (PPAR)-γ and the (pro)-inflammatory molecules cyclooxygenase 2 (COX2), tumor necrosis factor (TNF)-α and inducible Nitric oxide synthase (iNOS) immunohistochemically.PPAR-γ expression in APC tissues was found to be significantly higher than that in LPC and BPH specimens (p<0.001). In contrast, RXR-a expression was significantly lower (p<0.001). COX2 staining demonstrated a trend towards overexpression in APC (p=0.025). No significant differences were found for RAR-α, iNOS and TNF-α expression. Staining of FXR and LXR was seen diffusely in the cytoplasm as well as in the nucleus, preventing sufficient evaluation by definition.This study provides the basis for applying PPAR-γ ligands clinically in treatment of APC." @default.
W1878594902 created "2016-06-24" @default.
W1878594902 creator A5001390310 @default.
W1878594902 creator A5014763341 @default.
W1878594902 creator A5017566788 @default.
W1878594902 creator A5024511018 @default.
W1878594902 creator A5031580768 @default.
W1878594902 creator A5035341607 @default.
W1878594902 creator A5062089074 @default.
W1878594902 creator A5064942832 @default.
W1878594902 creator A5082458211 @default.
W1878594902 creator A5090289646 @default.
W1878594902 date "2012-08-01" @default.
W1878594902 modified "2023-10-16" @default.
W1878594902 title "Enhanced expression of peroxisome proliferate-activated receptor gamma (PPAR-γ) in advanced prostate cancer." @default.
W1878594902 cites W1495721125 @default.
W1878594902 cites W1984517945 @default.
W1878594902 cites W2003850828 @default.
W1878594902 cites W2019089252 @default.
W1878594902 cites W2024087814 @default.
W1878594902 cites W2024527855 @default.
W1878594902 cites W2028466182 @default.
W1878594902 cites W2029041730 @default.
W1878594902 cites W2031906658 @default.
W1878594902 cites W2034250583 @default.
W1878594902 cites W2041327710 @default.
W1878594902 cites W2047236275 @default.
W1878594902 cites W2054429544 @default.
W1878594902 cites W2057313230 @default.
W1878594902 cites W2062465243 @default.
W1878594902 cites W2067278135 @default.
W1878594902 cites W2072119701 @default.
W1878594902 cites W2072580525 @default.
W1878594902 cites W2084385092 @default.
W1878594902 cites W2084574319 @default.
W1878594902 cites W2085224017 @default.
W1878594902 cites W2091007186 @default.
W1878594902 cites W2123105952 @default.
W1878594902 cites W2162626606 @default.
W1878594902 cites W2165542862 @default.
W1878594902 cites W2340386540 @default.
W1878594902 cites W2405626778 @default.
W1878594902 cites W611065350 @default.
W1878594902 cites W2052964069 @default.
W1878594902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22843934" @default.
W1878594902 hasPublicationYear "2012" @default.
W1878594902 type Work @default.
W1878594902 sameAs 1878594902 @default.
W1878594902 citedByCount "20" @default.
W1878594902 countsByYear W18785949022015 @default.
W1878594902 countsByYear W18785949022016 @default.
W1878594902 countsByYear W18785949022017 @default.
W1878594902 countsByYear W18785949022018 @default.
W1878594902 countsByYear W18785949022019 @default.
W1878594902 countsByYear W18785949022021 @default.
W1878594902 countsByYear W18785949022022 @default.
W1878594902 crossrefType "journal-article" @default.
W1878594902 hasAuthorship W1878594902A5001390310 @default.
W1878594902 hasAuthorship W1878594902A5014763341 @default.
W1878594902 hasAuthorship W1878594902A5017566788 @default.
W1878594902 hasAuthorship W1878594902A5024511018 @default.
W1878594902 hasAuthorship W1878594902A5031580768 @default.
W1878594902 hasAuthorship W1878594902A5035341607 @default.
W1878594902 hasAuthorship W1878594902A5062089074 @default.
W1878594902 hasAuthorship W1878594902A5064942832 @default.
W1878594902 hasAuthorship W1878594902A5082458211 @default.
W1878594902 hasAuthorship W1878594902A5090289646 @default.
W1878594902 hasConcept C104317684 @default.
W1878594902 hasConcept C121608353 @default.
W1878594902 hasConcept C126322002 @default.
W1878594902 hasConcept C128821507 @default.
W1878594902 hasConcept C134018914 @default.
W1878594902 hasConcept C142724271 @default.
W1878594902 hasConcept C167400880 @default.
W1878594902 hasConcept C170493617 @default.
W1878594902 hasConcept C17991360 @default.
W1878594902 hasConcept C187345961 @default.
W1878594902 hasConcept C203862802 @default.
W1878594902 hasConcept C2776235491 @default.
W1878594902 hasConcept C2777562237 @default.
W1878594902 hasConcept C2780192828 @default.
W1878594902 hasConcept C502942594 @default.
W1878594902 hasConcept C55493867 @default.
W1878594902 hasConcept C63932345 @default.
W1878594902 hasConcept C71924100 @default.
W1878594902 hasConcept C86339819 @default.
W1878594902 hasConcept C86803240 @default.
W1878594902 hasConceptScore W1878594902C104317684 @default.
W1878594902 hasConceptScore W1878594902C121608353 @default.
W1878594902 hasConceptScore W1878594902C126322002 @default.
W1878594902 hasConceptScore W1878594902C128821507 @default.
W1878594902 hasConceptScore W1878594902C134018914 @default.
W1878594902 hasConceptScore W1878594902C142724271 @default.
W1878594902 hasConceptScore W1878594902C167400880 @default.
W1878594902 hasConceptScore W1878594902C170493617 @default.
W1878594902 hasConceptScore W1878594902C17991360 @default.
W1878594902 hasConceptScore W1878594902C187345961 @default.
W1878594902 hasConceptScore W1878594902C203862802 @default.